Smith & Nephew is trading at £1,171.00 (+5.19%), amid faster Q3 revenue growth.
- Q3 revenue growth accelerated to 3.4% from 1.6% in Q2; Sports Medicine & ENT rose 8%.
- Full-year revenue and profit guidance was cut amid weaker US orthopaedics demand, making the update mixed.
- A report linked gains in US-listed shares to improving growth, cash generation and pipeline, but did not establish the cause of the London share-price move.